Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING
More Virtual Banks to Switch On in Hong Kong
Geely’s Volvo Links Up With China Unicom on 5G for Self-Driving Cars
Property Giant Evergrande Pays 12% in New Bond Financing
LATEST
Tesla Switches to Baidu for In-Car Map Services
ByteDance Readying Assault on Tencent’s Mobile Gaming Kingdom
Hu Shuli: Reflections on Myanmar’s Leader
Property Giant Evergrande Pays 12% in New Bond Financing
More Virtual Banks to Switch On in Hong Kong
Geely’s Volvo Links Up With China Unicom on 5G for Self-Driving Cars
Investors Cash Out of Online Lender Qudian’s After Guidance Withdrawal
China-U.S. Trade Deal Hardly Addresses Issue of Technology Transfer
Tesla Eyes Design and Research Center for ‘Chinese-Style’ Cars
IPhone Manufacturer Gets Into Electric Cars Via Fiat Venture
Exclusive: Another PBOC Official Is Under Probe, Possibly Tied to Third-Party Payment
‘Chunyun’ Helps Travel-Related Apps Grow Their Active Users in December, Survey Shows
Rising Air Pollution Across China Clouds Clear Skies in Beijing and Shanghai: Report
Huawei Asks U.K. Developers to Help Build App Ecosystem Amid Android Ban
WeChat Tests Pay-to-Read Feature for Public Blogging Accounts
Listed Internet Firms Rally in Fourth Quarter
Beijing Media Company Enlight Announce One Billion Yuan Investment in Animation
JD.com Doubles Down on Smaller-Cities Expansion to Bolster 2020 Growth
Big China Tech Feasts, as Startups Go Hungry
Beyond Meat Shares Rise on Executive’s China Comments
Market Rattled by Kangmei’s $4.4 Billion Accounting Error

By Wang Juanjuan and Han Wei / May 01, 2019 12:37 AM / Finance

Photo: VCG

Photo: VCG

Shares and bonds of one of China’s largest listed drugmakers tumbled Tuesday after the company restated 29.9 billion yuan ($4.4 billion) of 2017 results, fueling suspicions of fraud.

Shanghai-listed Kangmei Pharmaceutical Co. Ltd., a producer of traditional Chinese medicines, said in a filing that there were multiple “accounting errors” in its 2017 results, leading to 29.9 billion yuan overstatement of the company’s cash holding. Late last year, Kangmei said it was investigated by securities regulators for suspected violations of information disclosure rules.

Kangmei’s stock, a component of MSCI Inc.’s global indexes, slumped by the 10% daily limit. The company’s bonds fell by 20%.

Several audit professionals said they were concerned that there may be problems in Kangmei’s financials beyond accounting errors, given the vague language and lack of logic in its correction statement. They said they suspected the company may have intentionally inflated its cash holding and inventories to boost profit.

Guangfa Securities and GP Certified Public Accountants Co. Ltd. have served in Kangmei’s financial and accounting operations.

Kangmei was involved in several bribery cases involving government officials. According to court documents released last June, the company bribed Cai Ming, former director of the drug safety supervision department at the Guangdong Province Food and Drug Administration, to the tune of 300,000 yuan from 2014 to 2015.

In February, the company was rattled by default risks on $300 million of bonds. The crisis was eased later after the Guangdong provincial government stepped in.

This story has been updated to correct the year of Kangmei’s financial report that contained errors. The report was for the year 2017, and it contained multiple errors.

Related: Pharmaceutical Firm Avoids Default as Guangdong Pressures Customers

Share this article
Open WeChat and scan the QR code